3D dose reconstruction based on in vivo dosimetry for determining the dosimetric impact of geometric variations in high-dose-rate prostate brachytherapy.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
06 2022
Historique:
received: 07 10 2021
revised: 30 12 2021
accepted: 04 01 2022
pubmed: 17 1 2022
medline: 9 6 2022
entrez: 16 1 2022
Statut: ppublish

Résumé

In vivo dosimetry (IVD) can be used for source tracking (ST), i.e., estimating source positions, during brachytherapy. The aim of this study was to exploit IVD-based ST to perform 3D dose reconstruction for high-dose-rate prostate brachytherapy and to evaluate the robustness of the treatments against observed geometric variations. Twenty-three fractions of high-dose-rate prostate brachytherapy were analysed. The treatment planning was based on MRI. Time-resolved IVD was performed using a fibre-coupled scintillator. ST was retrospectively performed using the IVD measurements. The ST identified 2D positional shifts of each treatment catheter and thereby inferred updated source positions. For each fraction, the dose was recalculated based on the source-tracked catheter positions and compared with the original plan dose using differences in dose volume histogram indices. Of 352 treatment catheters, 344 had shifts of less than 5 mm. Shifts between 5 and 10 mm were observed for 3 catheters, and shifts greater than 10 mm for 2 catheters. The ST failed for 3 catheters. The maximum relative difference in clinical target volume (prostate + 3 mm isotropic margin) D IVD-based 3D dose reconstruction for high-dose-rate prostate brachytherapy is feasible. The dosimetric impact of the observed catheter shifts was limited. Dose reconstruction can therefore aid in determining the dosimetric impact of geometric variations and errors in brachytherapy.

Identifiants

pubmed: 35033604
pii: S0167-8140(22)00009-3
doi: 10.1016/j.radonc.2022.01.006
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

62-68

Subventions

Organisme : NCI NIH HHS
ID : R01 CA120198
Pays : United States

Informations de copyright

Copyright © 2022. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Conflict of interest Nothing to report.

Auteurs

Erik B Jørgensen (EB)

Department of Clinical Medicine, Aarhus University, Denmark. Electronic address: erikjr@rm.dk.

Simon Buus (S)

Department of Oncology, Aarhus University Hospital, Denmark.

Lise Bentzen (L)

Department of Clinical Medicine, Aarhus University, Denmark; Department of Oncology, Aarhus University Hospital, Denmark.

Steffen B Hokland (SB)

Department of Oncology, Aarhus University Hospital, Denmark.

Susanne Rylander (S)

Department of Oncology, Aarhus University Hospital, Denmark.

Gustavo Kertzscher (G)

Department of Oncology, Aarhus University Hospital, Denmark.

Sam Beddar (S)

Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, USA.

Kari Tanderup (K)

Department of Clinical Medicine, Aarhus University, Denmark.

Jacob G Johansen (JG)

Department of Clinical Medicine, Aarhus University, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH